Study of Specimens From Young Patients With Neuroblastoma
RATIONALE: Studying the genes expressed in specimens from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at specimens from young patients with neuroblastoma.
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Prognostic Multigene Expression Classification of Neuroblastoma Patients|
- Establishment of mRNA gene expression classifier [ Time Frame: Length of study ] [ Designated as safety issue: No ]
- MicroRNA (miRNA) patterns that have prognostic significance in NB [ Time Frame: Length of study ] [ Designated as safety issue: No ]
- Better classification of NB tumors by analysis of the established microRNA classifier [ Time Frame: Length of study ] [ Designated as safety issue: No ]
|Study Start Date:||November 2008|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- Establish a robust mRNA gene expression classifier for improved outcome prediction in children with neuroblastoma by using real-time PCR to quantify mRNA levels from genes that have been shown in ≥ 2 independent studies to have predictive power.
- Identify microRNA (miRNA) patterns that have prognostic significance in NB as accumulating evidence indicates that alterations in miRNA expression play a critical role in tumorigenesis and can be used in prognostic evaluation.
- Perform an integrated analysis of the established microRNA classifier with our mRNA signature to determine whether it results in even better classification of NB tumors.
OUTLINE: Samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
PROJECTED ACCRUAL: A total of 150 samples from high-risk patients, 100 samples from medium-risk patients, and 100 samples from low-risk patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00958659
|United States, Pennsylvania|
|Childrens Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Michael Hogarty, MD 215-590-2821 email@example.com|
|Principal Investigator: Michael Hogarty, MD|
|Principal Investigator:||Michael D. Hogarty, MD||Children's Hospital of Philadelphia|